Loading…

Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma

Disulfidptosis, a novel form of regulated cell death, occurs due to the aberrant accumulation of intracellular cystine and other disulfides. Moreover, targeting disulfidptosis could identify promising approaches for cancer treatment. Long non-coding RNAs (lncRNAs) are known to be critically implicat...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2024-01, Vol.14 (1), p.624-624, Article 624
Main Authors: Wang, Ning, Hu, Yifeng, Wang, Shasha, Xu, Qin, Jiao, Xiaojing, Wang, Yanliang, Yan, Lei, Cao, Huixia, Shao, Fengmin
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c485t-f2683ae31e3db5c22445f3c3b429b905989e91c57533d07eba8b96a0d2fb00d23
cites cdi_FETCH-LOGICAL-c485t-f2683ae31e3db5c22445f3c3b429b905989e91c57533d07eba8b96a0d2fb00d23
container_end_page 624
container_issue 1
container_start_page 624
container_title Scientific reports
container_volume 14
creator Wang, Ning
Hu, Yifeng
Wang, Shasha
Xu, Qin
Jiao, Xiaojing
Wang, Yanliang
Yan, Lei
Cao, Huixia
Shao, Fengmin
description Disulfidptosis, a novel form of regulated cell death, occurs due to the aberrant accumulation of intracellular cystine and other disulfides. Moreover, targeting disulfidptosis could identify promising approaches for cancer treatment. Long non-coding RNAs (lncRNAs) are known to be critically implicated in clear cell renal cell carcinoma (ccRCC) development. Currently, the involvement of disulfidptosis-related lncRNAs in ccRCC is yet to be elucidated. This study primarily dealt with identifying and validating a disulfidptosis-related lncRNAs-based signature for predicting the prognosis and immune landscape of individuals with ccRCC. Clinical and RNA sequencing data of ccRCC samples were accessed from The Cancer Genome Atlas (TCGA) database. Pearson correlation analysis was conducted for the identification of the disulfidptosis-related lncRNAs. Additionally, univariate Cox regression analysis, Least Absolute Shrinkage and Selection Operator Cox regression, and stepwise multivariate Cox analysis were executed to develop a novel risk prognostic model. The prognosis-predictive capacity of the model was then assessed using an integrated method. Variation in biological function was noted using GO, KEGG, and GSEA. Additionally, immune cell infiltration, the tumor mutational burden (TMB), and tumor immune dysfunction and exclusion (TIDE) scores were calculated to investigate differences in the immune landscape. Finally, the expression of hub disulfidptosis-related lncRNAs was validated using qPCR. We established a novel signature comprised of eight lncRNAs that were associated with disulfidptosis (SPINT1-AS1, AL121944.1, AC131009.3, AC104088.3, AL035071.1, LINC00886, AL035587.2, and AC007743.1). Kaplan–Meier and receiver operating characteristic curves demonstrated the acceptable predictive potency of the model. The nomogram and C-index confirmed the strong correlation between the risk signature and clinical decision-making. Furthermore, immune cell infiltration analysis and ssGSEA revealed significantly different immune statuses among risk groups. TMB analysis revealed the link between the high-risk group and high TMB. It is worth noting that the cumulative effect of the patients belonging to the high-risk group and having elevated TMB led to decreased patient survival times. The high-risk group depicted greater TIDE scores in contrast with the low-risk group, indicating greater potential for immune escape. Finally, qPCR validated the hub disulfidptosis-related lnc
doi_str_mv 10.1038/s41598-024-51197-2
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_f4c562fae07942389a0bc0df64a08ee4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_f4c562fae07942389a0bc0df64a08ee4</doaj_id><sourcerecordid>2911840731</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-f2683ae31e3db5c22445f3c3b429b905989e91c57533d07eba8b96a0d2fb00d23</originalsourceid><addsrcrecordid>eNp9kcuOFSEQhjtG40zGeQEXhsSNm1au3bCcjLdJJpoYXRMaihNOaDhCt8k8ha8s5_Q4GheygErVxw9Vf9c9J_g1wUy-qZwIJXtMeS8IUWNPH3XnFHPRU0bp47_is-6y1j1uS1DFiXranTFJJB04Pe9-voUfEPNhhrSg7JFBKbcEcqGu0Qd3WHINtS8QzQIOxWS_fLpCNeySWdYCyOeCDiXvUq5LsMgkh8I8rwlQgXrIqUIrgwt2CTmhkJCNYAqyEGMjkolbaE2xIeXZPOueeBMrXN6fF9239---Xn_sbz9_uLm-uu0tl2LpPR0kM8AIMDcJSynnwjPLJk7VpHCbjAJFrBgFYw6PMBk5qcFgR_2E284uuptN12Wz14cSZlPudDZBnxK57LQpraMI2nMrBuoN4FFxyqQyeLLY-YEbLAF403q1abVBfF-hLnoO9diWSZDXqqkiRHI8MtLQl_-g-7yWNoYT1RAu1ZGiG2VLrrWAf_ggwfrovt7c1819fXJfHzt6cS-9TjO4hyu_vW4A24DaSmkH5c_b_5H9Ba7Yu7s</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2910734891</pqid></control><display><type>article</type><title>Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma</title><source>Publicly Available Content Database</source><source>PubMed</source><source>Free Full-Text Journals in Chemistry</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Wang, Ning ; Hu, Yifeng ; Wang, Shasha ; Xu, Qin ; Jiao, Xiaojing ; Wang, Yanliang ; Yan, Lei ; Cao, Huixia ; Shao, Fengmin</creator><creatorcontrib>Wang, Ning ; Hu, Yifeng ; Wang, Shasha ; Xu, Qin ; Jiao, Xiaojing ; Wang, Yanliang ; Yan, Lei ; Cao, Huixia ; Shao, Fengmin</creatorcontrib><description>Disulfidptosis, a novel form of regulated cell death, occurs due to the aberrant accumulation of intracellular cystine and other disulfides. Moreover, targeting disulfidptosis could identify promising approaches for cancer treatment. Long non-coding RNAs (lncRNAs) are known to be critically implicated in clear cell renal cell carcinoma (ccRCC) development. Currently, the involvement of disulfidptosis-related lncRNAs in ccRCC is yet to be elucidated. This study primarily dealt with identifying and validating a disulfidptosis-related lncRNAs-based signature for predicting the prognosis and immune landscape of individuals with ccRCC. Clinical and RNA sequencing data of ccRCC samples were accessed from The Cancer Genome Atlas (TCGA) database. Pearson correlation analysis was conducted for the identification of the disulfidptosis-related lncRNAs. Additionally, univariate Cox regression analysis, Least Absolute Shrinkage and Selection Operator Cox regression, and stepwise multivariate Cox analysis were executed to develop a novel risk prognostic model. The prognosis-predictive capacity of the model was then assessed using an integrated method. Variation in biological function was noted using GO, KEGG, and GSEA. Additionally, immune cell infiltration, the tumor mutational burden (TMB), and tumor immune dysfunction and exclusion (TIDE) scores were calculated to investigate differences in the immune landscape. Finally, the expression of hub disulfidptosis-related lncRNAs was validated using qPCR. We established a novel signature comprised of eight lncRNAs that were associated with disulfidptosis (SPINT1-AS1, AL121944.1, AC131009.3, AC104088.3, AL035071.1, LINC00886, AL035587.2, and AC007743.1). Kaplan–Meier and receiver operating characteristic curves demonstrated the acceptable predictive potency of the model. The nomogram and C-index confirmed the strong correlation between the risk signature and clinical decision-making. Furthermore, immune cell infiltration analysis and ssGSEA revealed significantly different immune statuses among risk groups. TMB analysis revealed the link between the high-risk group and high TMB. It is worth noting that the cumulative effect of the patients belonging to the high-risk group and having elevated TMB led to decreased patient survival times. The high-risk group depicted greater TIDE scores in contrast with the low-risk group, indicating greater potential for immune escape. Finally, qPCR validated the hub disulfidptosis-related lncRNAs in cell lines. The established novel signature holds potential regarding the prognosis prediction of individuals with ccRCC as well as predicting their responses to immunotherapy.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-024-51197-2</identifier><identifier>PMID: 38182642</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/114/2397 ; 631/67/1857 ; 692/4025/2768/1588/1351 ; 692/4028/67/589/1588/1351 ; Cancer therapies ; Cell death ; Clear cell-type renal cell carcinoma ; Correlation analysis ; Decision making ; Genomes ; Humanities and Social Sciences ; Immune response ; Immunotherapy ; Infiltration ; Kidney cancer ; Medical prognosis ; Metastases ; multidisciplinary ; Non-coding RNA ; Patients ; Prognosis ; Regression analysis ; Risk groups ; Science ; Science (multidisciplinary) ; Tumors</subject><ispartof>Scientific reports, 2024-01, Vol.14 (1), p.624-624, Article 624</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-f2683ae31e3db5c22445f3c3b429b905989e91c57533d07eba8b96a0d2fb00d23</citedby><cites>FETCH-LOGICAL-c485t-f2683ae31e3db5c22445f3c3b429b905989e91c57533d07eba8b96a0d2fb00d23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2910734891/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2910734891?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,37013,44590,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38182642$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Ning</creatorcontrib><creatorcontrib>Hu, Yifeng</creatorcontrib><creatorcontrib>Wang, Shasha</creatorcontrib><creatorcontrib>Xu, Qin</creatorcontrib><creatorcontrib>Jiao, Xiaojing</creatorcontrib><creatorcontrib>Wang, Yanliang</creatorcontrib><creatorcontrib>Yan, Lei</creatorcontrib><creatorcontrib>Cao, Huixia</creatorcontrib><creatorcontrib>Shao, Fengmin</creatorcontrib><title>Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Disulfidptosis, a novel form of regulated cell death, occurs due to the aberrant accumulation of intracellular cystine and other disulfides. Moreover, targeting disulfidptosis could identify promising approaches for cancer treatment. Long non-coding RNAs (lncRNAs) are known to be critically implicated in clear cell renal cell carcinoma (ccRCC) development. Currently, the involvement of disulfidptosis-related lncRNAs in ccRCC is yet to be elucidated. This study primarily dealt with identifying and validating a disulfidptosis-related lncRNAs-based signature for predicting the prognosis and immune landscape of individuals with ccRCC. Clinical and RNA sequencing data of ccRCC samples were accessed from The Cancer Genome Atlas (TCGA) database. Pearson correlation analysis was conducted for the identification of the disulfidptosis-related lncRNAs. Additionally, univariate Cox regression analysis, Least Absolute Shrinkage and Selection Operator Cox regression, and stepwise multivariate Cox analysis were executed to develop a novel risk prognostic model. The prognosis-predictive capacity of the model was then assessed using an integrated method. Variation in biological function was noted using GO, KEGG, and GSEA. Additionally, immune cell infiltration, the tumor mutational burden (TMB), and tumor immune dysfunction and exclusion (TIDE) scores were calculated to investigate differences in the immune landscape. Finally, the expression of hub disulfidptosis-related lncRNAs was validated using qPCR. We established a novel signature comprised of eight lncRNAs that were associated with disulfidptosis (SPINT1-AS1, AL121944.1, AC131009.3, AC104088.3, AL035071.1, LINC00886, AL035587.2, and AC007743.1). Kaplan–Meier and receiver operating characteristic curves demonstrated the acceptable predictive potency of the model. The nomogram and C-index confirmed the strong correlation between the risk signature and clinical decision-making. Furthermore, immune cell infiltration analysis and ssGSEA revealed significantly different immune statuses among risk groups. TMB analysis revealed the link between the high-risk group and high TMB. It is worth noting that the cumulative effect of the patients belonging to the high-risk group and having elevated TMB led to decreased patient survival times. The high-risk group depicted greater TIDE scores in contrast with the low-risk group, indicating greater potential for immune escape. Finally, qPCR validated the hub disulfidptosis-related lncRNAs in cell lines. The established novel signature holds potential regarding the prognosis prediction of individuals with ccRCC as well as predicting their responses to immunotherapy.</description><subject>631/114/2397</subject><subject>631/67/1857</subject><subject>692/4025/2768/1588/1351</subject><subject>692/4028/67/589/1588/1351</subject><subject>Cancer therapies</subject><subject>Cell death</subject><subject>Clear cell-type renal cell carcinoma</subject><subject>Correlation analysis</subject><subject>Decision making</subject><subject>Genomes</subject><subject>Humanities and Social Sciences</subject><subject>Immune response</subject><subject>Immunotherapy</subject><subject>Infiltration</subject><subject>Kidney cancer</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>multidisciplinary</subject><subject>Non-coding RNA</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Regression analysis</subject><subject>Risk groups</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Tumors</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kcuOFSEQhjtG40zGeQEXhsSNm1au3bCcjLdJJpoYXRMaihNOaDhCt8k8ha8s5_Q4GheygErVxw9Vf9c9J_g1wUy-qZwIJXtMeS8IUWNPH3XnFHPRU0bp47_is-6y1j1uS1DFiXranTFJJB04Pe9-voUfEPNhhrSg7JFBKbcEcqGu0Qd3WHINtS8QzQIOxWS_fLpCNeySWdYCyOeCDiXvUq5LsMgkh8I8rwlQgXrIqUIrgwt2CTmhkJCNYAqyEGMjkolbaE2xIeXZPOueeBMrXN6fF9239---Xn_sbz9_uLm-uu0tl2LpPR0kM8AIMDcJSynnwjPLJk7VpHCbjAJFrBgFYw6PMBk5qcFgR_2E284uuptN12Wz14cSZlPudDZBnxK57LQpraMI2nMrBuoN4FFxyqQyeLLY-YEbLAF403q1abVBfF-hLnoO9diWSZDXqqkiRHI8MtLQl_-g-7yWNoYT1RAu1ZGiG2VLrrWAf_ggwfrovt7c1819fXJfHzt6cS-9TjO4hyu_vW4A24DaSmkH5c_b_5H9Ba7Yu7s</recordid><startdate>20240105</startdate><enddate>20240105</enddate><creator>Wang, Ning</creator><creator>Hu, Yifeng</creator><creator>Wang, Shasha</creator><creator>Xu, Qin</creator><creator>Jiao, Xiaojing</creator><creator>Wang, Yanliang</creator><creator>Yan, Lei</creator><creator>Cao, Huixia</creator><creator>Shao, Fengmin</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><general>Nature Portfolio</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>20240105</creationdate><title>Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma</title><author>Wang, Ning ; Hu, Yifeng ; Wang, Shasha ; Xu, Qin ; Jiao, Xiaojing ; Wang, Yanliang ; Yan, Lei ; Cao, Huixia ; Shao, Fengmin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-f2683ae31e3db5c22445f3c3b429b905989e91c57533d07eba8b96a0d2fb00d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>631/114/2397</topic><topic>631/67/1857</topic><topic>692/4025/2768/1588/1351</topic><topic>692/4028/67/589/1588/1351</topic><topic>Cancer therapies</topic><topic>Cell death</topic><topic>Clear cell-type renal cell carcinoma</topic><topic>Correlation analysis</topic><topic>Decision making</topic><topic>Genomes</topic><topic>Humanities and Social Sciences</topic><topic>Immune response</topic><topic>Immunotherapy</topic><topic>Infiltration</topic><topic>Kidney cancer</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>multidisciplinary</topic><topic>Non-coding RNA</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Regression analysis</topic><topic>Risk groups</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Ning</creatorcontrib><creatorcontrib>Hu, Yifeng</creatorcontrib><creatorcontrib>Wang, Shasha</creatorcontrib><creatorcontrib>Xu, Qin</creatorcontrib><creatorcontrib>Jiao, Xiaojing</creatorcontrib><creatorcontrib>Wang, Yanliang</creatorcontrib><creatorcontrib>Yan, Lei</creatorcontrib><creatorcontrib>Cao, Huixia</creatorcontrib><creatorcontrib>Shao, Fengmin</creatorcontrib><collection>SpringerOpen(OpenAccess)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Ning</au><au>Hu, Yifeng</au><au>Wang, Shasha</au><au>Xu, Qin</au><au>Jiao, Xiaojing</au><au>Wang, Yanliang</au><au>Yan, Lei</au><au>Cao, Huixia</au><au>Shao, Fengmin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2024-01-05</date><risdate>2024</risdate><volume>14</volume><issue>1</issue><spage>624</spage><epage>624</epage><pages>624-624</pages><artnum>624</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Disulfidptosis, a novel form of regulated cell death, occurs due to the aberrant accumulation of intracellular cystine and other disulfides. Moreover, targeting disulfidptosis could identify promising approaches for cancer treatment. Long non-coding RNAs (lncRNAs) are known to be critically implicated in clear cell renal cell carcinoma (ccRCC) development. Currently, the involvement of disulfidptosis-related lncRNAs in ccRCC is yet to be elucidated. This study primarily dealt with identifying and validating a disulfidptosis-related lncRNAs-based signature for predicting the prognosis and immune landscape of individuals with ccRCC. Clinical and RNA sequencing data of ccRCC samples were accessed from The Cancer Genome Atlas (TCGA) database. Pearson correlation analysis was conducted for the identification of the disulfidptosis-related lncRNAs. Additionally, univariate Cox regression analysis, Least Absolute Shrinkage and Selection Operator Cox regression, and stepwise multivariate Cox analysis were executed to develop a novel risk prognostic model. The prognosis-predictive capacity of the model was then assessed using an integrated method. Variation in biological function was noted using GO, KEGG, and GSEA. Additionally, immune cell infiltration, the tumor mutational burden (TMB), and tumor immune dysfunction and exclusion (TIDE) scores were calculated to investigate differences in the immune landscape. Finally, the expression of hub disulfidptosis-related lncRNAs was validated using qPCR. We established a novel signature comprised of eight lncRNAs that were associated with disulfidptosis (SPINT1-AS1, AL121944.1, AC131009.3, AC104088.3, AL035071.1, LINC00886, AL035587.2, and AC007743.1). Kaplan–Meier and receiver operating characteristic curves demonstrated the acceptable predictive potency of the model. The nomogram and C-index confirmed the strong correlation between the risk signature and clinical decision-making. Furthermore, immune cell infiltration analysis and ssGSEA revealed significantly different immune statuses among risk groups. TMB analysis revealed the link between the high-risk group and high TMB. It is worth noting that the cumulative effect of the patients belonging to the high-risk group and having elevated TMB led to decreased patient survival times. The high-risk group depicted greater TIDE scores in contrast with the low-risk group, indicating greater potential for immune escape. Finally, qPCR validated the hub disulfidptosis-related lncRNAs in cell lines. The established novel signature holds potential regarding the prognosis prediction of individuals with ccRCC as well as predicting their responses to immunotherapy.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>38182642</pmid><doi>10.1038/s41598-024-51197-2</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2045-2322
ispartof Scientific reports, 2024-01, Vol.14 (1), p.624-624, Article 624
issn 2045-2322
2045-2322
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_f4c562fae07942389a0bc0df64a08ee4
source Publicly Available Content Database; PubMed; Free Full-Text Journals in Chemistry; Springer Nature - nature.com Journals - Fully Open Access
subjects 631/114/2397
631/67/1857
692/4025/2768/1588/1351
692/4028/67/589/1588/1351
Cancer therapies
Cell death
Clear cell-type renal cell carcinoma
Correlation analysis
Decision making
Genomes
Humanities and Social Sciences
Immune response
Immunotherapy
Infiltration
Kidney cancer
Medical prognosis
Metastases
multidisciplinary
Non-coding RNA
Patients
Prognosis
Regression analysis
Risk groups
Science
Science (multidisciplinary)
Tumors
title Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T19%3A49%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20a%20novel%20disulfidptosis-related%20lncRNA%20signature%20for%20prognostic%20and%20immune%20response%20prediction%20in%20clear%20cell%20renal%20cell%20carcinoma&rft.jtitle=Scientific%20reports&rft.au=Wang,%20Ning&rft.date=2024-01-05&rft.volume=14&rft.issue=1&rft.spage=624&rft.epage=624&rft.pages=624-624&rft.artnum=624&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-024-51197-2&rft_dat=%3Cproquest_doaj_%3E2911840731%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c485t-f2683ae31e3db5c22445f3c3b429b905989e91c57533d07eba8b96a0d2fb00d23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2910734891&rft_id=info:pmid/38182642&rfr_iscdi=true